CHARACTERIZATION OF BETA THALASSAEMIA MUTATIONS IN PATIENTS HAVING BORDERLINE HAEMOGLOBIN A2 LEVELS
DOI:
https://doi.org/10.55519/JAMC-04-14046Keywords:
Borderline HbA2, Silent carriers, Beta Thalassaemia mutation, Red Cell Indices, Molecular analysis.Abstract
Background: The occurrence of a single beta thalassaemia allele is frequently related with microcytic hypochromic red blood cells and a rise in HbA2 levels. In some beta thalassaemia carriers, the outcome of this allele or its collaboration with other acquired or genetic defects may result in normal or borderline Haemoglobin bA2 levels. Objective was to establish the importance of molecular analysis in borderline HbA2 individuals and its significance in a population screening program. Methods: It was a cross-sectional study conducted over a period of six months, from July-December 2023. All 123 individuals with borderline HbA2 levels between (3‒3.9%) diagnosed by High-performance liquid chromatography (HPLC)/Capillary Zone Electrophoresis underwent molecular testing using multiplex amplification refractory mutation system-Polymerase Chain Reaction (ARMS-PCR) to detect common beta thalassaemia mutations: Fr8-9, IVS1-5, Fr41-42, Cd15, Cd5, IVS1-1, IVS1-1, Cd30, Cd30, Fr16, IVSII-1, Del619, and CAP+1 in the Department of Haematology, Armed Forces Institute of Pathology, Rawalpindi .Statistical tests were applied to compare Red Blood Cell indices and Haemoglobin A2 values among beta thalassaemia carriers and non-carriers. Results: Among those tested, 47.1% (n=58) were found to carry Beta thalassaemia mutations. The most prevalent mutations were IVS1-5 (n=19,15.4%) and Fr8-9 (n=19,15.4%) followed by Fr41-42 (n=08,6.5%). Subjects with mutations exhibited significantly lower mean corpuscular volume and mean corpuscular haemoglobin compared to those without mutations (p-value= <0.001). Beta thalassaemia mutations were seen more frequently when HbA2 was in range of 3.5-3.9% (n=37,63.8%), as compared to HbA2 that was 3-3.4% (n=21,36.2%) and this difference was found to be significant (p-value= <0.001). The CAP+1 mutation was associated (n=02,1.6%) with normal mean MCV and MCH compared to other identified mutations. Conclusions: It is concluded that molecular study for the common beta thalassaemia mutations in Pakistani population plays a pivotal role in confirmation of borderline HbA2 thalassaemia carriers, specifically in areas with a high prevalence of the disease. Molecular testing for beta thalassaemia should be offered to all individuals with borderline HbA2 with values especially between 3.4‒3.9% and having microcytic hypochromic indices.
References
1. Moradi K, Alibakhshi R, Shafieenia S, Azimi A. Problem of borderline hemoglobin A2 levels in an Iranian population with a high prevalence of α-and β-thalassemia carriers. Egypt J Med Hum Genet 2022;23(1):61.
2. Paleari R, Giambona A, Cannata M, Leto F, Maggio A, Mosca A, et al. External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems. Clin Chem Lab Med 2007;45(1):88–92.
3. Thilakarathne S, Jayaweera UP, Premawardhena A. Unresolved laboratory issues of the heterozygous state of β-thalassemia: a literature review. Haematologica 2024;109(1):23–32.
4. Srivorakun H, Thawinan W, Fucharoen G, Sanchaisuriya K, Fucharoen S. Thalassemia and erythroid transcription factor KLF1 mutations associated with borderline hemoglobin A2 in the Thai population. Arch Med Sci 2022;18(1):112–20.
5. Zhao Y, Jiang F, Li DZ. Hematological Characteristics of β-Globin Gene Mutation–50 (G> A)(HBB: c.-100G> A) Carriers in Mainland China. Hemoglobin 2020;44(4):240–3.
6. Dell’Edera D, Sarlo F, Epifania AA, Lupo MG. When the study of the globin genes is useful? 2017.
7. Origa R. Beta-thalassemia. 2021.
8. Theodoridou S, Balassopoulou A, Boutou E, Delaki EE, Yfanti E, Vyzantiadis TA, et al. Coinheritance of triplicated alpha-globin gene and beta-thalassemia mutations in adulthood: ten years of referrals in northern Greece. J Pediatr Hematol Oncol 2020;42(8):e762–4.
9. Khan AM, Al-Sulaiti AM, Younes S, Yassin M, Zayed H. The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review. Expert Rev Hematol 2021;14(1):109–22.
10. Hammoud H, Ghanem R, Abdalla R, Semaan P, Azzi J, Prada EP, et al. Genetic mutations of beta thalassemia in middle east countries. World J Pharm Pharm Sci 2020;9(2):134–50.
11. Thaker P, Mahajan N, Mukherjee MB, Colah RB. Wide spectrum of novel and rare hemoglobin variants in the multi‐ethnic Indian population: A review. Int J Lab Hematol 2024;46(3):434–50.
12. Colaco S, Nadkarni A. Borderline HbA2 levels: dilemma in diagnosis of beta-thalassemia carriers. Mutat Res Rev Mutat Res 2021;788:108387.
13. Colah R, Italia K, Gorakshakar A. Burden of thalassemia in India: the road map for control. Pediatr Hematol Oncol J 2017;2(4):79–84.
14. Ahmed S. Genetic haemoglobin disorders in Pakistan. Natl J Health Sci 2017;2(3):95–9.
15. Ansari SH, Shamsi TS, Bohray M, Khan MT, Farzana T, Perveen K, et al. Molecular epidemiology of β-thalassemia in Pakistan: far reaching implications. Int J Mol Epidemiol Genet 2011;2(4):403–8.
16. Satthakarn S, Panyasai S, Pornprasert S. Molecular characterization of β-and α-globin gene mutations in individuals with borderline hb a2 levels. Hemoglobin 2020;44(5):349–53.
17. Saif S, Lila S, Ghani G, Rahat MA, Rasool A, Israr M. Clinical Insights: Prevalence of β-Thalassemia Mutations (IVSI-5, FSC8/9, and CD41/42) in the Swat District. J Bio-X Res 2024;7:0004.
18. Sumedha D, Anita K. Prevalence of beta thalassemia carriers in India: a systematic review and meta-analysis. J Community Genet 2023;14(6):527–41.
19. Zulkeflee RH, Bahar R, Abdullah M, Mohd Radzi MAR, Md Fauzi A, Hassan R. Application of targeted next-generation sequencing for the investigation of thalassemia in a developing country: A single center experience. Diagnostics (Basel) 2023;13(8):1379.
20. Chaweephisal P, Phusua A, Fanhchaksai K, Sirichotiyakul S, Charoenkwan P. Borderline hemoglobin A2 levels in northern Thai population: HBB genotypes and effects of coinherited alpha-thalassemia. Blood Cells Mol Dis 2019;74:13–7.
21. Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med 2013;3(5):a011700.
22. Abdul Karim MU, Moinuddin M, Babar SU. Cap+ 1 mutation; an unsuspected cause of beta thalassaemia transmission in Pakistan. Turk J Haematol 2009;26(4):167–70.
23. Kaur G, Chatterjee T, Ahuja A, Sen A. Challenges in diagnosis of thalassemia syndromes. Med J Armed Forces India 2024;80(6):632–7.
24. Tariq R, Sikandar N, Akhtar S, Bashir S, Farooq MU. Significance of Molecular Analysis in a Population Screening Program for Identification of Silent Beta Thalassemia Carriers in a Country with High Disease Prevalence. J Haematol Stem Cell Res 2022;2(2):68–72.
25. Rosnah B, Shahida N, Nazri M, Marini R, Noor Haslina M, Shafini M. The diagnosis of beta thalassemia with borderline HbA2 level among Kelantan population. J Blood Disord Transfus 2017;8(396):2.
26. Stephanou C, Petrou M, Kountouris P, Makariou C, Christou S, Hadjigavriel M, et al. Unravelling the Complexity of the+ 33 C> G [HBB: c.-18C> G] Variant in Beta Thalassemia. Biomedicines 2024;12(2):296.
27. Catapano R, Sessa R, Trombetti S, Cesaro E, Russo F, Izzo P, et al. Identification and functional analysis of known and new mutations in the transcription factor KLF1 linked with β-thalassemia-like phenotypes. Biology (Basel) 2023;12(4):510.
28. Cheema AN, Khanum R, Hamid S. Impact of Iron deficiency on diagnosis of Beta Thalassemia Trait. Prof Med J 2020;27(04):849–52.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Afshan Noor, Manzar Bozdar, Hamid Saeed Malik, Rafia Mehmood, Ayesha Khursheed, Ayesha Khan, Nighat Seema
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
